Novel caveolin modulators as therapeutics for uveitis

新型小窝蛋白调节剂治疗葡萄膜炎

基本信息

批准号：
9140245
负责人：
David D Eveleth
金额：
$ 3.5万
依托单位：
E AND B TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-01 至 2017-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9140245
关键词：
Acute Adverse event Affect Age Animal Model Antigens Autoimmune encephalitis Blindness Blood Vessels Caveolae Caveolins Cells Chronic Chronic Disease Clinical Clinical Trials Collaborations Development Disease Dose Drug Kinetics Edema Elements Experimental Models Extravasation Generations Genus Mycobacterium Goals Gold Health Health Sciences Human Hybrid Cells Immunomodulators Immunosuppressive Agents Inflammation Inflammatory Laboratories Lead Leukocytes Modeling Mus Oregon Oryctolagus cuniculus Outcome Measure Patients Peptides Pharmaceutical Preparations Phase Process RIII Mouse Research Research Proposals Retinal Route Saturn&apos s Moon Phoebe Signal Transduction Technology Therapeutic Toxic effect Toxicology Universities Uveitis Vascular Permeabilities Vision Visual impairment Work analog autoimmune uveitis base disability improved inflammatory modulation intravitreal injection killings migration mouse model novel novel therapeutics prevent primary outcome research clinical testing research study response retinal damage scaffold

项目摘要

DESCRIPTION (provided by applicant): Novel caveolin modulators as therapeutics for uveitis Project Summary This research proposal seeks to develop a novel therapy for uveitis based upon modulation of inflammatory signaling via caveolae. Uveitis drives 5-20% of blindness, affecting people of working age and producing significant disability in patients with chronic disease. Caveolin modulators such as cavtratin are known to be able to modulate inflammatory signaling including edema and leukocyte migration, key elements of the pathogenic cascade in uveitis. E&B Technologies is developing an improved, second generation cavtratin, CVX-001, for the treatment of uveitis. The project goal is to demonstrate that CVX-001 can prevent retinal inflammation in mouse and rabbit models of uveitis and, in phase II, IND enabling work completed. Longer term, proof of concept in human clinical testing will be pursued and the clinical trials needed for regulatory approval will be conducted. Successful completion of this project will establish a new therapeutic option for uveitis sufferers with a reduction in blindness and visual impairment. 1

描述（由申请人提供）：新型小凹蛋白调节剂作为葡萄膜炎的治疗剂项目摘要本研究计划旨在开发一种基于通过小凹蛋白调节炎症信号传导的新型葡萄膜炎疗法。葡萄膜炎导致 5-20% 的失明，影响工作年龄的人，并导致慢性病患者严重残疾。已知小窝蛋白调节剂如cavtratin能够调节炎症信号传导，包括水肿和白细胞迁移，这是葡萄膜炎致病级联的关键要素。 E&B Technologies 正在开发一种改进的第二代 cavtratin CVX-001，用于治疗葡萄膜炎。该项目的目标是证明 CVX-001 可以预防小鼠和兔子葡萄膜炎模型中的视网膜炎症，并在第二阶段完成 IND 工作。从长远来看，将寻求人体临床测试的概念验证，并进行监管批准所需的临床试验。该项目的成功完成将为葡萄膜炎患者建立新的治疗选择，减少失明和视力障碍。 1